• A 4/6, 5/6 or 6/6 HLA matched related or unrelated UCB unit available that will deliver a pre-cryopreservation total nucleated cell dose of ≥ 3 x 10e7 cells/kg, or double unit grafts, each cord blood unit delivering at least 2 x 10e7 cells/kg OR an 8 of 8 or 7 of 8 HLA allele level matched unrelated donor bone marrow or peripheral blood progenitor graft.

• Adequate organ function as measured by:

‣ Creatinine ≤ 2.0 mg/dL and creatinine clearance ≥ 50 mL/min/1.73 m2.

⁃ Hepatic transaminases (ALT/AST) ≤ 4 x upper limit of normal (ULN).

⁃ Adequate cardiac function by echocardiogram or radionuclide scan (shortening fraction \> 26% or ejection fraction \> 40% or \> 80% of normal value for age).

⁃ Pulmonary evaluation testing demonstrating CVC or FEV1/FVC of ≥ 50% of predicted for age and/or resting pulse oximeter ≥ 92% on room air or clearance by the pediatric or adult pulmonologist. For adult patients DLCO (corrected for hemoglobin) should be ≥ 50% of predicted if the DLCO can be obtained.

• Written informed consent and/or assent according to FDA guidelines.

• Negative pregnancy test if pubertal and/or menstruating.

• HIV negative.

• A non-malignant disorder amenable to treatment by stem cell transplantation, including but not limited to:

‣ Primary Immunodeficiency syndromes including but not limited to:

• Severe Combined Immune Deficiency (SCID) with NK cell activity

∙ Omenn Syndrome

∙ Bare Lymphocyte Syndrome (BLS)

∙ Combined Immune Deficiency (CID) syndromes

∙ Combined Variable Immune Deficiency (CVID) syndrome

∙ Wiskott-Aldrich Syndrome

∙ Leukocyte adhesion deficiency

∙ Chronic granulomatous disease (CGD)

∙ X-linked Hyper IgM (XHIM) syndrome

∙ IPEX syndrome

∙ Chediak - Higashi Syndrome

∙ Autoimmune Lymphoproliferative Syndrome (ALPS)

∙ Hemophagocytic Lymphohistiocytosis (HLH) syndromes

∙ Lymphocyte Signaling defects

∙ Other primary immune defects where hematopoietic stem cell transplantation may be beneficial

⁃ Congenital bone marrow failure syndromes including but not limited to:

• Dyskeratosis Congenita (DC)

∙ Congenital Amegakaryocytic Thrombocytopenia (CAMT)

∙ Osteopetrosis

⁃ Inherited Metabolic Disorders (IMD) including but not limited to:

• Mucopolysaccharidoses

‣ Hurler syndrome (MPS I)

⁃ Hunter syndrome (MPS II)

∙ Leukodystrophies

‣ Krabbe Disease, also known as globoid cell leukodystrophy

⁃ Metachromatic leukodystrophy (MLD)

⁃ X-linked adrenoleukodystrophy (ALD)

⁃ Hereditary diffuse leukoencephalopathy with spheroids (HDLS)

∙ Other inherited metabolic disorders

‣ alpha mannosidosis

⁃ Gaucher Disease

∙ Other inheritable metabolic diseases where hematopoietic stem cell transplantation may be beneficial.

⁃ Hereditary anemias

• Thalassemia major

∙ Sickle cell disease (SCD) - patients with sickle disease must have one or more of the following:

‣ Overt or silent stroke

⁃ Pain crises ≥ 2 episodes per year for past year

⁃ One or more episodes of acute chest syndrome

⁃ Osteonecrosis involving ≥ 1 joints

⁃ Priapism

∙ Diamond Blackfan Anemia (DBA)

∙ Other congenital transfusion dependent anemias

⁃ Inflammatory Conditions

• Crohn's Disease/Inflammatory Bowel Disease